Simon P Rugera, Hope Mudondo, Jazira Tumusiime, Rahma Udu, Ritah Kiconco, Sylvia A Lumumba, Charles N Bagenda
{"title":"Association of obesity with hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.","authors":"Simon P Rugera, Hope Mudondo, Jazira Tumusiime, Rahma Udu, Ritah Kiconco, Sylvia A Lumumba, Charles N Bagenda","doi":"10.4102/ajlm.v14i1.2565","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperuricaemia is a risk factor for gout and independently predicts hypertension, diabetes, and chronic kidney disease development. While elevated uric acid levels occur in HIV patients, and weight gain is linked to dolutegravir-based therapy, data on the obesity-hyperuricaemia relationship in this population remain limited.</p><p><strong>Objective: </strong>The objective of our study was to evaluate the association between obesity and hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.</p><p><strong>Methods: </strong>Between April 2024 and June 2024, this study conducted a secondary analysis of data on uric acid level and factors associated with obesity from a 2023 cross-sectional study of HIV-positive participants. We used logistic regression to assess the factors associated with hyperuricaemia, and receiver operating characteristic curve analysis to assess the predictive performance of body mass index for hyperuricaemia.</p><p><strong>Results: </strong>Among 328 participants, hyperuricaemia prevalence was 23.48% (95% confidence interval [CI]: 19.19-28.39%) higher in male participants (31.6%) than female participants (20.0%, <i>p</i> = 0.023). Overweight (adjusted odds ratio [aOR]: 2.01; 95% CI: 1.01-4.00; <i>p</i> = 0.046), obesity (aOR: 2.50; 95% CI: 1.09-5.73, <i>p</i> = 0.030), and male gender (aOR: 2.31; 95% CI: 1.07-5.01, <i>p</i> = 0.033) were significantly associated with hyperuricaemia.</p><p><strong>Conclusion: </strong>Our findings indicate a relationship between hyperuricaemia and obesity in HIV patients on antiretroviral therapy in Uganda. Nationwide studies using primary data are needed to better understand this relationship's epidemiological spread.</p><p><strong>What this study adds: </strong>This study is the first to link obesity with hyperuricaemia among HIV-positive Ugandans on antiretroviral therapy, highlighting obesity as a key metabolic complication of HIV treatment.</p>","PeriodicalId":45412,"journal":{"name":"African Journal of Laboratory Medicine","volume":"14 1","pages":"2565"},"PeriodicalIF":1.0000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886560/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4102/ajlm.v14i1.2565","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hyperuricaemia is a risk factor for gout and independently predicts hypertension, diabetes, and chronic kidney disease development. While elevated uric acid levels occur in HIV patients, and weight gain is linked to dolutegravir-based therapy, data on the obesity-hyperuricaemia relationship in this population remain limited.
Objective: The objective of our study was to evaluate the association between obesity and hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.
Methods: Between April 2024 and June 2024, this study conducted a secondary analysis of data on uric acid level and factors associated with obesity from a 2023 cross-sectional study of HIV-positive participants. We used logistic regression to assess the factors associated with hyperuricaemia, and receiver operating characteristic curve analysis to assess the predictive performance of body mass index for hyperuricaemia.
Results: Among 328 participants, hyperuricaemia prevalence was 23.48% (95% confidence interval [CI]: 19.19-28.39%) higher in male participants (31.6%) than female participants (20.0%, p = 0.023). Overweight (adjusted odds ratio [aOR]: 2.01; 95% CI: 1.01-4.00; p = 0.046), obesity (aOR: 2.50; 95% CI: 1.09-5.73, p = 0.030), and male gender (aOR: 2.31; 95% CI: 1.07-5.01, p = 0.033) were significantly associated with hyperuricaemia.
Conclusion: Our findings indicate a relationship between hyperuricaemia and obesity in HIV patients on antiretroviral therapy in Uganda. Nationwide studies using primary data are needed to better understand this relationship's epidemiological spread.
What this study adds: This study is the first to link obesity with hyperuricaemia among HIV-positive Ugandans on antiretroviral therapy, highlighting obesity as a key metabolic complication of HIV treatment.
期刊介绍：
The African Journal of Laboratory Medicine, the official journal of ASLM, focuses on the role of the laboratory and its professionals in the clinical and public healthcare sectors,and is specifically based on an African frame of reference. Emphasis is on all aspects that promote and contribute to the laboratory medicine practices of Africa. This includes, amongst others: laboratories, biomedical scientists and clinicians, medical community, public health officials and policy makers, laboratory systems and policies (translation of laboratory knowledge, practices and technologies in clinical care), interfaces of laboratory with medical science, laboratory-based epidemiology, laboratory investigations, evidence-based effectiveness in real world (actual) settings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
